Receptor tyrosine kinases (RTKs) are the 58-member family of membrane receptors that transduce growth factors: an extracellular ligand-binding domain, a single transmembrane helix, and an intracellular kinase that, when ligand dimerises the receptor, trans-phosphorylates its partner's tyrosines — creating the docking sites that assemble the RAS-ERK and PI3K-AKT pathways. EGFR/HER2, insulin receptor, VEGFR, FGFR, MET, KIT: the family runs development, metabolism, angiogenesis, and immunity — and mutated into constitutive signalling, it drives the majority of human cancers. RTK inhibitors are oncology's most-used targeted drugs.
Extracellular domains are immunoglobulin- or cysteine-rich modules arranged for ligand-induced dimerisation; the insulin receptor is a preformed disulfide-linked dimer with a folded-over kinase.
The kinase domain's activation loop, juxtamembrane wedge, and C-tail tail hold it autoinhibited until dimerisation aligns the pair for trans-phosphorylation — the switch's mechanics.
Phosphotyrosines are read by SH2/PTB domains of signalling proteins — phosphorylation as an address system, see MAPK wiring.
Function
Growth and survival: EGF-family and FGF signalling drive proliferation through RAS-RAF-MEK-ERK, survival through PI3K-AKT; receptor specificity is tissue and ligand encoded.
Metabolism: the insulin receptor's IRS-protein cascade is the RTK family's metabolic arm — glucose uptake and storage, see insulin.
Vascular and organogenesis programs: VEGFR in angiogenesis, KIT in melanocytes and hematopoiesis, MET in liver regeneration and invasive growth — the RTK map of organs.
Regulation
Endocytosis and degradation (Cbl-mediated ubiquitination) attenuate signalling; dephosphorylation by PTPs resets — both are tumor-suppressive losses when broken.
Activating lesions — HER2 amplification, EGFR L858R, KIT D816V, ALK/RET fusions — jam the switch on; each has its approved inhibitor.
Interactions
Downstream: RAS via GRB2-SOS; PI3K p85 direct binding; PLCγ for the calcium arm — the three standard outlets.
With growth factors as ligands — the pair that defines paracrine growth control.
With anti-RTK therapy: antibodies (trastuzumab, cetuximab, bevacizumab) outside, small-molecule TKIs (erlotinib, sunitinib, crizotinib, osimertinib) inside — the two-drug strategy on one receptor.
Clinical Relevance
Oncology mainstay: HER2 breast cancer, EGFR-mutant lung adenocarcinoma, GIST (KIT), renal cell (VEGFR), ALK/RET/NTRK fusions — biomarker-matched TKI therapy is standard of care across dozens of indications.
Resistance biology: T790M-type gatekeeper mutations, bypass signalling, lineage switch — the field's ongoing chess game driving next-generation inhibitors.
Developmental syndromes: gain-of-function FGFR3 (achondroplasia — now treatable with vosoritide-adjacent strategies), Crouzon; loss-of-function KIT or RET pathways in Hirschsprung's and congenital aganglionosis.